|
|
|
|
| LEADER |
02700nam a2200301 u 4500 |
| 001 |
EB001839717 |
| 003 |
EBX01000000000000001003706 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 245 |
0 |
0 |
|a Gabapentin for adults with neuropathic pain
|h Elektronische Ressource
|b a review of the clinical efficacy and safety
|c prepared by Canadian Agency for Drugs and Technologies in Health
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH Rapid Response Service
|c [2015], 2015
|
| 300 |
|
|
|a 1 PDF file (29 pages)
|b illustration
|
| 653 |
|
|
|a Amines / therapeutic use
|
| 653 |
|
|
|a Neuralgia / drug therapy
|
| 653 |
|
|
|a Anticonvulsants / therapeutic use
|
| 653 |
|
|
|a Cyclohexanecarboxylic Acids / therapeutic use
|
| 653 |
|
|
|a Treatment Outcome
|
| 653 |
|
|
|a gamma-Aminobutyric Acid / therapeutic use
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|b Rapid Response Service
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Rapid response report: summary with critical appraisal
|
| 500 |
|
|
|a Title from PDF caption. - "14 April 2015."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK304850
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Pharmacological management of neuropathic pain (NP) includes medications such as anticonvulsants, antidepressants, serotonin noradrenaline reuptake inhibitors, opioid analgesics, cannabinoids and methadone. Gabapentin is an anticonvulsant and has been used to manage neuropathic pain. Gabapentin is not without side effects and there is also potential for misuse. Side effects associated with gabapentin include somnolence, dizziness, peripheral edema and gait disturbances. Gabapentinoids (including gabapentin) in high doses may result in sedative and psychedelic effects. Gabapentin is structurally related to the neurotransmitter gamma aminobutyric acid (GABA) but does not bind to the GABA receptors. Its mechanism of action is through binding to calcium channels and modulating the influx of calcium and thereby bestowing antiepileptic, analgesic and sedative effects. Recent research also suggests that gabapentin acts by blocking new synapse formation. Gabapentin is available in various dosages and formulations. Besides the immediate release gabapentin there is an extended release, gastro-retentive formulation and an extended release gabapentin prodrug (enacarbil) that rapidly hydrolyses to gabapentin. The purpose of this report is to review the clinical efficacy and safety of gabapentin compared with placebo in adults with neuropathic pain
|